statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others...

FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter PeptiDream) (Tokyo: 4587) today announced an expansion of its peptide...

PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds...

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

 US equity futures swung between gains and losses and traded near session highs as US traders...

Futures Rise, Yen Downgraded To Banana Republic Currency After Another Rollercoaster Session

Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
read...

Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook

Novartis CEO: Broadly Positive About Business Momentum...

Novartis CEO: Broadly Positive About Business Momentum

Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results...

Shares of Novartis climb 4.8% on raised guidance, better-than-expected results

Novartis Raises Guidance on Profit, Sales Growth...

Novartis Raises Guidance on Profit, Sales Growth

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

 Hot on the heels of last week's tech and momentum rout, shaken traders will have to wait until Friday for the main...

Key Events This Week: PCE, GDP, Fed Blackout And Earnings Gallore

It's been a busy week for Swiss healthcare giant Novartis. In a series of days, the company said it's slowing trials of its blockbuster cancer drug and slashing hundreds of jobs and attempting to...

Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Volume	872,620.00
52-Wk High	$108.78
52-Wk Low	$88.90

Period	Estimated	Reported	Surprise	Result
Q2'24	$1.83	--	--	N/A
Q1'24	$1.68	$1.80	7.42%	BEAT
Q4'23	$1.65	$1.53	-7.11%	MISSED
Q3'23	$1.67	$1.74	4.37%	BEAT
Q2'23	$1.64	$1.73	5.81%	BEAT

NVS Novartis AG

About

Feed

News

Sentiment

Earnings

Fundamentals